What is Arrhythmogenic right ventricular cardiomyopathy?
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare inherited heart muscle disease that primarily affects the right ventricle, causing progressive replacement of healthy heart muscle with fibrous and fatty tissue. This condition disrupts the heart’s electrical system, leading to dangerous arrhythmias (irregular heartbeats) that can cause sudden cardiac death, particularly in young athletes. ARVC affects approximately 1 in 2,000 to 5,000 people worldwide, making it one of the more common causes of sudden cardiac death in people under 35. The condition is caused by mutations in genes that produce proteins essential for connecting heart muscle cells, leading to progressive deterioration of heart muscle structure and function.
Key statistics
| Prevalence | 1 in 2,000–5,000 people |
| Age of onset | Usually 20-40 years, can occur in teens |
| Inheritance pattern | Autosomal dominant (50% chance of passing to children) |
| Sudden cardiac death risk | 2-3% annually without treatment |
Symptoms
Common symptoms: Palpitations, chest pain, shortness of breath, fainting (syncope), fatigue, exercise intolerance, dizziness.
The symptoms of ARVC often develop gradually and may initially be subtle. Palpitations are frequently the first symptom, described as a racing, fluttering, or irregular heartbeat that may last seconds to hours. Syncope (fainting) or near-fainting episodes often occur during physical exertion and represent a serious warning sign of dangerous arrhythmias. Chest pain may occur during exercise or at rest and can be sharp or aching. Shortness of breath typically worsens with activity as the heart’s pumping ability becomes compromised. Some patients experience chronic fatigue and reduced exercise tolerance as the condition progresses. In tragic cases, sudden cardiac death may be the first and only symptom, highlighting the importance of family screening and early detection.
Causes and risk factors
ARVC is primarily caused by mutations in genes that produce desmosomal proteins—structures that act like molecular glue to hold heart muscle cells together. The most commonly affected genes include PKP2 (plakophilin-2), DSP (desmoplakin), DSG2 (desmoglein-2), DSC2 (desmocollin-2), and JUP (junction plakoglobin). These mutations follow an autosomal dominant inheritance pattern, meaning only one copy of the mutated gene from either parent is sufficient to cause the disease.
Risk factors include having a family history of ARVC or sudden cardiac death, particularly in young relatives. Intense endurance exercise may accelerate disease progression in genetically susceptible individuals, as the repeated stretching and contracting of the heart during vigorous activity can worsen the structural abnormalities. Male athletes appear to be at higher risk for developing symptoms at an earlier age. Environmental factors such as viral infections may trigger disease onset in genetically predisposed individuals.
Prevention
Since ARVC is a genetic condition, it cannot be prevented in the traditional sense. However, genetic testing and family screening are crucial for early detection and prevention of sudden cardiac death. First-degree relatives of affected individuals should undergo comprehensive cardiac evaluation including electrocardiogram, echocardiogram, and genetic counseling. Genetic testing can identify at-risk family members before symptoms develop, allowing for preventive measures such as activity restrictions and regular monitoring.
For diagnosed patients, avoiding high-intensity competitive sports and endurance activities can help slow disease progression and reduce the risk of life-threatening arrhythmias. Preconception genetic counseling is recommended for individuals with ARVC who are planning families, as each child has a 50% chance of inheriting the condition.
Complications
Without proper treatment, ARVC can lead to severe and life-threatening complications. The most serious is sudden cardiac death due to ventricular tachycardia or ventricular fibrillation—rapid, chaotic heart rhythms that prevent effective blood circulation. Progressive heart failure develops as healthy heart muscle is gradually replaced by fibrous and fatty tissue, reducing the heart’s ability to pump blood effectively.
Chronic arrhythmias can cause persistent symptoms and increase stroke risk due to blood clot formation. As the disease progresses, it may extend beyond the right ventricle to affect the left ventricle, worsening the prognosis. Tricuspid regurgitation (leaky tricuspid valve) commonly develops, further compromising heart function. Some patients develop pulmonary embolism due to blood clots forming in the damaged right ventricle.
Diagnosis
Diagnosing ARVC requires a comprehensive approach using the revised Task Force Criteria, which incorporate clinical, genetic, and imaging findings. Electrocardiogram (ECG) may show characteristic epsilon waves—small deflections after the QRS complex—along with T-wave inversions in right-sided leads and prolonged QRS duration in right precordial leads.
Echocardiography and cardiac magnetic resonance imaging (MRI) are essential for evaluating right ventricular structure and function, detecting wall motion abnormalities, and identifying fatty or fibrous infiltration. Holter monitoring or event monitors capture arrhythmias that may not occur during routine ECG. Exercise stress testing can provoke arrhythmias and assess exercise tolerance.
Genetic testing identifies disease-causing mutations in approximately 50-60% of patients. Endomyocardial biopsy is rarely performed but may show characteristic tissue changes. Signal-averaged ECG can detect late potentials that indicate areas of slow electrical conduction.
Treatment
Treatment focuses on preventing sudden cardiac death and managing symptoms. Implantable cardioverter defibrillators (ICDs) are the cornerstone of treatment for high-risk patients, automatically detecting and treating life-threatening arrhythmias. ICDs are recommended for patients with sustained ventricular tachycardia, survived cardiac arrest, or high-risk features.
Antiarrhythmic medications help control symptoms and reduce arrhythmia burden. Sotalol and amiodarone are commonly used, though amiodarone requires careful monitoring for side effects. Flecainide may be used in select cases.
For heart failure symptoms, standard medications include ACE inhibitors, beta-blockers, and diuretics. Activity restrictions are crucial—patients should avoid competitive sports and high-intensity exercise. Catheter ablation may help control recurrent ventricular tachycardia. In end-stage disease, heart transplantation may be necessary.
Prognosis
The prognosis for ARVC varies significantly depending on disease severity, genetic mutation, and treatment response. With appropriate treatment including ICD implantation when indicated, many patients can live relatively normal lives with good quality of life. The annual risk of sudden cardiac death decreases substantially with ICD protection, though patients remain at risk for device shocks and progressive heart failure.
Factors associated with better prognosis include early diagnosis, appropriate activity restrictions, and compliance with treatment. Left ventricular involvement and sustained ventricular tachycardia indicate more advanced disease with worse prognosis. While ARVC is progressive, the rate of progression varies widely among individuals. Some patients experience slowly progressive disease over decades, while others may have rapid deterioration. Regular follow-up with specialized electrophysiologists is essential for monitoring disease progression and adjusting treatment.
Quality of life
Living with ARVC requires significant lifestyle adjustments, but many patients maintain good quality of life with proper management. Exercise modifications are essential—while competitive sports and high-intensity activities are restricted, low-to-moderate intensity recreational activities like walking, swimming, and cycling are generally safe and beneficial for overall health.
Dietary considerations include maintaining a heart-healthy diet low in sodium if heart failure develops. Stress management is important since emotional stress can trigger arrhythmias. Regular sleep patterns help optimize heart rhythm stability. Many patients experience anxiety about their condition and benefit from counseling or support groups.
Work considerations depend on individual circumstances, but most patients can continue their careers with some modifications. Jobs requiring heavy physical labor or those where sudden incapacitation could endanger others (like commercial driving) may need to be avoided. Travel is generally safe with proper preparation and ensuring access to medical care.
Pregnancy and fertility
Pregnancy in women with ARVC requires specialized care but is often possible with appropriate monitoring. The hemodynamic changes of pregnancy may increase arrhythmia risk, and some antiarrhythmic medications may need adjustment or discontinuation due to potential fetal effects. Beta-blockers are generally considered safe during pregnancy.
Preconception counseling is essential to discuss genetic risks, optimize medications, and plan monitoring strategies. ICDs remain functional during pregnancy and delivery, though device settings may need adjustment. Most women can deliver vaginally, though cesarean section may be preferred in high-risk cases. Genetic counseling should address the 50% risk of passing the condition to offspring and discuss available genetic testing options.
Children
ARVC rarely manifests before puberty, but adolescents with family history require careful evaluation, especially if participating in sports. Children of affected parents should undergo baseline cardiac evaluation around age 10-12, with genetic testing considered after appropriate counseling. Activity restrictions in asymptomatic gene-positive children remain controversial and require individualized assessment.
Psychological support is crucial for children and adolescents dealing with activity restrictions and genetic implications. Family screening protocols should include age-appropriate education about the condition and its implications for lifestyle and future family planning.
When to see a doctor
Seek emergency care immediately for chest pain with shortness of breath, fainting episodes, sustained rapid heart rate, or severe dizziness. Any family history of sudden cardiac death in relatives under 50 warrants urgent cardiac evaluation.
Schedule routine cardiology consultation for recurring palpitations, decreased exercise tolerance, or if you have family members diagnosed with ARVC. Annual follow-up is recommended for diagnosed patients, with more frequent visits if symptoms change or device issues arise.
Regional context
Limited data exists on ARVC prevalence specifically in the Caucasus region (Georgia, Armenia, Azerbaijan) and broader Eastern Mediterranean area. Founder effects and genetic isolates in some populations may influence local prevalence and genetic mutation patterns. The Global Medical Journal welcomes contributions from regional researchers and clinicians to better understand ARVC epidemiology and outcomes in these populations.
Research and clinical trials
Current research focuses on gene therapy approaches, novel antiarrhythmic strategies, and improved risk stratification methods. Studies are investigating the role of inflammation in disease progression and potential anti-inflammatory treatments. Advances in cardiac imaging, particularly cardiac MRI techniques, are improving diagnostic accuracy and monitoring capabilities.
Clinical trials are evaluating new antiarrhythmic drugs, catheter ablation techniques, and genetic therapies. The ARVC registry studies continue to provide insights into natural history and treatment outcomes. Patients can find relevant clinical trials at ClinicalTrials.gov using search terms “arrhythmogenic right ventricular cardiomyopathy” and “ARVC.”
Frequently asked questions
Can I exercise if I have ARVC?
Competitive and high-intensity sports should be avoided, but low-to-moderate intensity recreational activities like walking, easy cycling, and swimming are generally safe and beneficial. Always discuss activity plans with your cardiologist.
Will my children definitely inherit ARVC?
Each child has a 50% chance of inheriting the genetic mutation. However, having the mutation doesn’t guarantee symptoms will develop, and genetic counseling can help families understand their specific risks and options.
Do I need an ICD if I have no symptoms?
ICD recommendations depend on multiple factors including genetic mutation type, family history, test results, and individual risk assessment. Even asymptomatic patients may benefit from ICD protection in certain circumstances.
How often do I need follow-up appointments?
Typically annually for stable patients, but more frequently if symptoms change, after device implantation, or medication adjustments. Your cardiologist will determine the appropriate schedule based on your individual situation.
Can ARVC be cured?
Currently, there is no cure for ARVC, but treatments can effectively prevent sudden cardiac death and manage symptoms. Research into gene therapy and regenerative approaches offers hope for future curative treatments.
Support and resources
• ARVC/ARVD Foundation: https://www.arvd.org
• Johns Hopkins ARVC Program: https://www.hopkinsmedicine.org/heart_vascular_institute/conditions_treatments/conditions/arvc.html
• Sudden Arrhythmia Death Syndromes (SADS) Foundation: https://www.sads.org
• Orphanet: https://www.orpha.net
• National Organization for Rare Disorders (NORD): https://rarediseases.org
• EURORDIS (European Organisation for Rare Diseases): https://www.eurordis.org
• Global Alliance for the Future of Food (GAFF): https://futureoffood.org
Related conditions
• Hypertrophic cardiomyopathy
• Dilated cardiomyopathy
• Brugada syndrome
• Catecholaminergic polymorphic ventricular tachycardia
• Long QT syndrome
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Arrhythmogenic right ventricular cardiomyopathy.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/arrhythmogenic-right-ventricular-cardiomyopathy/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?